Physician profile
Steven P Schmidt
NPI 1396770517
$16,622.64
in general payments reported to CMS, 2019-2025
58 companies · $2,456 in 2025
The $2,456 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,586 · 2020: $1,607 · 2021: $2,560 · 2022: $2,248 · 2023: $3,092 · 2024: $3,074 · 2025: $2,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,289 · Education: $241 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,288.79 |
| Education | $241.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,989.74 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,949.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,744.91 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,495.26 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $1,162.52 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,045.71 | 2019-2025 | |
| Novo Nordisk INC | $1,023.76 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $826.72 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $481.00 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $428.91 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.24 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $315.61 | 2020-2025 | Rexulti, Abilify Asimtufii |
| Sanofi-Aventis U.S. LLC | $258.07 | 2019-2022 | |
| Mylan Specialty L.P. | $230.27 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $220.46 | 2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.